Cargando…

Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential

Background: Colorectal cancer represents a common malignancy and remains incurable in the metastatic stage. Identification of molecular alterations that are present in colorectal cancer has led to the introduction of targeted therapies that improve outcomes. BRAF and PIK3CA mutations are observed in...

Descripción completa

Detalles Bibliográficos
Autor principal:	Voutsadakis, Ioannis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608248/ https://www.ncbi.nlm.nih.gov/pubmed/36295658 http://dx.doi.org/10.3390/medicina58101498

Ejemplares similares

The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Patra, Satyajit, et al.
Publicado: (2017)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Dirican, Ebubekir
Publicado: (2020)

Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer
por: Wang, Chengfeng, et al.
Publicado: (2022)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
por: Shetty, Omshree, et al.
Publicado: (2022)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
por: Mao, Chen, et al.
Publicado: (2012)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer
por: Reggiani Bonetti, Luca, et al.
Publicado: (2018)

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
por: Velho, Sérgia, et al.
Publicado: (2008)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017)

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
por: Guo, Fang, et al.
Publicado: (2018)

Targeting glutamine metabolism in PIK3CA mutant colorectal cancers
por: Feng, Xiujing, et al.
Publicado: (2016)

PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
por: Wang, Qiang, et al.
Publicado: (2018)

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
por: Zeng, Juanzi, et al.
Publicado: (2023)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
por: Hall, Daniella C. N., et al.
Publicado: (2022)

mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial
por: Shen, Cailu, et al.
Publicado: (2022)

Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA
por: Chang, Li-Chun, et al.
Publicado: (2014)

Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases
por: Mao, Chen, et al.
Publicado: (2015)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
por: Palomba, Grazia, et al.
Publicado: (2016)

Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status
por: Jenniskens, Josien C. A., et al.
Publicado: (2022)

KRAS , NRAS , BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
por: Mirzapoor Abbasabadi, Zohreh, et al.
Publicado: (2023)

PIK3CA mutation and colorectal cancer precision medicine
por: Hamada, Tsuyoshi, et al.
Publicado: (2017)

Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
por: Zhang, Jing, et al.
Publicado: (2015)

BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
por: Nam, Soo Kyung, et al.
Publicado: (2016)

Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients
por: Li, Xiaozhou, et al.
Publicado: (2018)

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2(nd) Line Cetuximab-Based Therapy of Colorectal Cancer Patients
por: Saridaki, Zacharenia, et al.
Publicado: (2011)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
por: Palomba, Grazia, et al.
Publicado: (2012)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
por: Baltruškevičienė, Edita, et al.
Publicado: (2016)

Energy balance‐related factors in childhood and adolescence and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status
por: Jenniskens, Josien C. A., et al.
Publicado: (2022)

Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas()()
por: Myers, Meagan B., et al.
Publicado: (2016)

BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy
por: Colombino, M, et al.
Publicado: (2012)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

PIK3CA mutation in a case of CTNNB1-mutant sinonasal glomangiopericytoma
por: Hong, Christopher S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3t9svaj2huuookjtqo435q8tkm